ReviewCancers2022
Exploring the Biological and Physical Basis of Boron Neutron Capture Therapy (BNCT) as a Promising Treatment Frontier in Breast Cancer.
Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 40 citations in OpenAlex.
- Elemental Boron Nanoparticles for Boron-Neutron Capture Therapy of BT-474 Human Breast Cancer.Nanomaterials (Basel, Switzerland) · 2026Article
- Beyond radiation: immunological potentials of boron neutron capture therapy.Cancer immunology, immunotherapy : CII · 2026Review
- Exploring the Use of Boron Neutron Capture Therapy for Recurrent Breast Cancer and Brain Metastases: A Case Series.Advances in radiation oncology · 2026Article
- Article
- Core clinical procedures and efficacy-enhancing strategies in boron neutron capture therapy.Discover oncology · 2026Review
- ADMET-Guided Design and In Silico Planning of Boron Delivery Systems for BNCT: From Transport and Biodistribution to PBPK-Informed Irradiation Windows.Molecules (Basel, Switzerland) · 2026Review
- Potential targets for boron transport in boron neutron capture therapy.Frontiers in oncology · 2026Review
- Clinical application of boron neutron capture therapy for cancer treatment: A systematic review.Precision radiation oncology · 2025Review
- Assessment of Carrier-Free Metallacarboranes for Targeted Radiation Therapies PBFT and BNCT: Comparative Cellular Effects and Dosimetry Studies with [Pharmaceuticals (Basel, Switzerland) · 2025Article
- Article
- Development of LAT1-Selective Nuclear Medicine Therapeutics Using Astatine-211.International journal of molecular sciences · 2024Article
- Boron Neutron Capture Therapy-Derived Extracellular Vesicles via DNA Accumulation Boost Antitumor Dendritic Cell Vaccine Efficacy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Micronutrient Status and Breast Cancer: A Narrative Review.International journal of molecular sciences · 2024Review
- The impact of solute carrier proteins on disrupting substance regulation in metabolic disorders: insights and clinical applications.Frontiers in pharmacology · 2024Review
- Enhancing Cancer Therapy: Boron-Rich Polyboronate Ester Micelles for Synergistic Boron Neutron Capture Therapy and PD-1/PD-L1 Checkpoint Blockade.Biomaterials research · 2024Article
- Peptide Conjugated Boron Neutron Capture Therapy for Enhanced Tumor Targeting.Nanotheranostics · 2024Review
- Investigation of the Impact of L-Phenylalanine and L-Tyrosine Pre-Treatment on the Uptake of 4-Borono-L-Phenylalanine in Cancerous and Normal Cells Using an Analytical Approach Based on SC-ICP-MS.Molecules (Basel, Switzerland) · 2023Article
- Article
- Recent Development of Radiofluorination of Boron Agents for Boron Neutron Capture Therapy of Tumor: Creation ofPharmaceuticals (Basel, Switzerland) · 2023Review
- The role of radiolabeling in BNCT tracers for enhanced dosimetry and treatment planning.Theranostics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BNCT is a high LET radiation therapy modality that allows for biologically targeted radiation delivery to tumors while reducing normal tissue impacts. Although the clinical use of BNCT has largely been limited to phase I/II trials and has primarily focused on difficult-to-treat malignancies such as recurrent head and neck cancer and recurrent gliomas, recently there has been a renewed interest in expanding the use of BNCT to other disease sites, including breast cancer. Given its high LET characteristics, its biologically targeted and tumor specific nature, as well as its potential for use in complex treatment settings including reirradiation and widespread metastatic disease, BNCT offers several unique advantages over traditional external beam radiation therapy. The two main boron compounds investigated to date in BNCT clinical trials are BSH and BPA. Of these, BPA in particular shows promise in breast cancer given that is taken up by the LAT-1 amino acid transporter that is highly overexpressed in breast cancer cells. As the efficacy of BNCT is directly dependent on the extent of boron accumulation in tumors, extensive preclinical efforts to develop novel boron delivery agents have been undertaken in recent years. Preclinical studies have shown promise in antibody linked boron compounds targeting ER/HER2 receptors, boron encapsulating liposomes, and nanoparticle-based boron delivery systems. This review aims to summarize the physical and biological basis of BNCT, the preclinical and limited clinical data available to date, and discuss its potential to be utilized for the successful treatment of various breast cancer disease states.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.